NCT02145065View on ClinicalTrials.gov

First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

October 31, 2017

Conditions

Peripheral Artery DiseaseFemoropopliteal Artery Disease

Interventions

DRUG

Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)

DEVICE

Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)

Trial Locations (1)

32-500

Lesser-Poland Cardiovascular Center of American Heart of Poland, Chrzanów

All Listed Sponsors

collaborator

American Heart of Poland

OTHER

lead

Balton Sp.zo.o.

INDUSTRY

NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) | Biotech Hunter | Biotech Hunter